SWKH - Enteris Biopharma sees growth opportunities in 2021 with potential partnerships in the works

Biotechnology company Enteris BioPharma, wholly owned subsidiary of SWK Holdings ([[SWKH]] +0.2%), forecasts growth opportunities this year and says that it will actively pursue partnership discussions with companies seeking US domestic CDMO capabilities.Will advance activities to secure partnerships with pharmaceutical and biotech companies to develop oral tablet formulations of molecules with low oral bioavailability using its novel technology.Enteris also highlights its 2020 achievements:During 2020, Enteris appointed Rajiv Khosla as its Chief Executive Officer, and named Gary Shangold Chief Medical Officer.Completed construction of its expanded manufacturing facility enabling Enteris to produce clinical trial material ((CTM)) through to Phase 3 development.Received two separate milestone payments from Cara totalling $5M in relation to the ongoing development of an oral formulation of Cara's KOR agonist, CR845/difelikefalin ((Oral KORSUVA)).The company is eligible to receive additional potential milestone payments for Oral KORSUVA in 2021.

For further details see:

Enteris Biopharma sees growth opportunities in 2021 with potential partnerships in the works